Literature DB >> 24018949

Differential patterns of replacement and reactive fibrosis in pressure and volume overload are related to the propensity for ischaemia and involve resistin.

Elie R Chemaly1, Soojeong Kang, Shihong Zhang, LaTronya McCollum, Jiqiu Chen, Ludovic Bénard, K-Raman Purushothaman, Roger J Hajjar, Djamel Lebeche.   

Abstract

Pathological left ventricle (LV) hypertrophy (LVH) results in reactive and replacement fibrosis. Volume overload LVH (VOH) is less profibrotic than pressure overload LVH (POH). Studies attribute subendocardial fibrosis in POH to ischaemia, and reduced fibrosis in VOH to collagen degradation favouring dilatation. However, the mechanical origin of the relative lack of fibrosis in VOH is incompletely understood. We hypothesized that reduced ischaemia propensity in VOH compared to POH accounted for the reduced replacement fibrosis, along with reduced reactive fibrosis. Rats with POH (ascending aortic banding) evolved into either compensated-concentric POH (POH-CLVH) or dilated cardiomyopathy (POH-DCM); they were compared to VOH (aorta-caval fistula). We quantified LV fibrosis, structural and haemodynamic factors of ischaemia propensity, and the activation of profibrotic pathways. Fibrosis in POH-DCM was severe, subendocardial and subepicardial, in contrast with subendocardial fibrosis in POH-CLVH and nearly no fibrosis in VOH. The propensity for ischaemia was more important in POH versus VOH, explaining different patterns of replacement fibrosis. LV collagen synthesis and maturation, and matrix metalloproteinase-2 expression, were more important in POH. The angiotensin II-transforming growth-factor β axis was enhanced in POH, and connective tissue growth factor (CTGF) was overexpressed in all types of LVH. LV resistin expression was markedly elevated in POH, mildly elevated in VOH and independently reflected chronic ischaemic injury after myocardial infarction. In vitro, resistin is induced by angiotensin II and induces CTGF in cardiomyocytes. Based on these findings, we conclude that a reduced ischaemia propensity and attenuated upstream reactive fibrotic pathways account for the attenuated fibrosis in VOH versus POH.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24018949      PMCID: PMC3936371          DOI: 10.1113/jphysiol.2013.258731

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  61 in total

Review 1.  Volume overload.

Authors:  Blase A Carabello
Journal:  Heart Fail Clin       Date:  2012-01       Impact factor: 3.179

2.  Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation.

Authors:  Ronen Beeri; Chaim Yosefy; J Luis Guerrero; Francesca Nesta; Suzan Abedat; Miguel Chaput; Federica del Monte; Mark D Handschumacher; Robert Stroud; Suzanne Sullivan; Thea Pugatsch; Dan Gilon; Gus J Vlahakes; Francis G Spinale; Roger J Hajjar; Robert A Levine
Journal:  J Am Coll Cardiol       Date:  2008-01-29       Impact factor: 24.094

3.  Myocardial oxygen consumption during exercise in the presence of left ventricular hypertrophy secondary to supravalvular aortic stenosis.

Authors:  R J Bache; X Z Dai
Journal:  J Am Coll Cardiol       Date:  1990-04       Impact factor: 24.094

4.  Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats.

Authors:  Elie R Chemaly; Lahouaria Hadri; Shihong Zhang; Maengjo Kim; Erik Kohlbrenner; Jipo Sheng; Lifan Liang; Jiqiu Chen; Purushothaman K-Raman; Roger J Hajjar; Djamel Lebeche
Journal:  J Mol Cell Cardiol       Date:  2011-04-23       Impact factor: 5.000

5.  Effectiveness of beta-blockade in experimental chronic aortic regurgitation.

Authors:  Eric Plante; Dominic Lachance; Martin Gaudreau; Marie-Claude Drolet; Elise Roussel; Marie Arsenault; Jacques Couet
Journal:  Circulation       Date:  2004-09-07       Impact factor: 29.690

6.  Comparison of echocardiographic measurements of left ventricular volumes to full volume magnetic resonance imaging in normal and diseased rats.

Authors:  Teresa Arias; Jiqiu Chen; Zahi A Fayad; Valentin Fuster; Roger J Hajjar; Elie R Chemaly
Journal:  J Am Soc Echocardiogr       Date:  2013-05-23       Impact factor: 5.251

7.  Role of resistin in cardiac contractility and hypertrophy.

Authors:  Maengjo Kim; Jae Kyun Oh; Susumu Sakata; Iifan Liang; Woojin Park; Roger J Hajjar; Djamel Lebeche
Journal:  J Mol Cell Cardiol       Date:  2008-05-20       Impact factor: 5.000

8.  Effects of spironolactone treatment on an experimental model of chronic aortic valve regurgitation.

Authors:  Adnane Zendaoui; Dominic Lachance; Elise Roussel; Jacques Couet; Marie Arsenault
Journal:  J Heart Valve Dis       Date:  2012-07

9.  Quantitation of left ventricular myocardial fiber hypertrophy and interstitial tissue in human hearts with chronically increased volume and pressure overload.

Authors:  V Fuster; M A Danielson; R A Robb; J C Broadbent; A L Brown; L R Elveback
Journal:  Circulation       Date:  1977-03       Impact factor: 29.690

10.  Survival, exercise capacity, and left ventricular remodeling in a rat model of chronic mitral regurgitation: serial echocardiography and pressure-volume analysis.

Authors:  Kyung-Hee Kim; Yong-Jin Kim; Seung-Pyo Lee; Hyung-Kwan Kim; Jeong-Wook Seo; Dae-Won Sohn; Byung-Hee Oh; Young-Bae Park
Journal:  Korean Circ J       Date:  2011-10-31       Impact factor: 3.243

View more
  13 in total

1.  Heme is involved in the exogenous ALA-promoted growth and antioxidant defense system of cucumber seedlings under salt stress.

Authors:  Yue Wu; Jing Li; Junwen Wang; Mohammed Mujitaba Dawuda; Weibiao Liao; Xin Meng; Hong Yuan; Jianming Xie; Zhongqi Tang; Jian Lyu; Jihua Yu
Journal:  BMC Plant Biol       Date:  2022-07-08       Impact factor: 5.260

2.  Connective tissue growth factor regulates cardiac function and tissue remodeling in a mouse model of dilated cardiomyopathy.

Authors:  Yevgeniya E Koshman; Mark D Sternlicht; Taehoon Kim; Christopher P O'Hara; Christopher A Koczor; William Lewis; Todd W Seeley; Kenneth E Lipson; Allen M Samarel
Journal:  J Mol Cell Cardiol       Date:  2015-11-05       Impact factor: 5.000

3.  Diabetic cardiomyopathy: is resistin a culprit?

Authors:  Djamel Lebeche
Journal:  Cardiovasc Diagn Ther       Date:  2015-10

4.  Resistin induces cardiac fibroblast-myofibroblast differentiation through JAK/STAT3 and JNK/c-Jun signaling.

Authors:  Rajvir Singh; Ravinder K Kaundal; Baoyin Zhao; Rihab Bouchareb; Djamel Lebeche
Journal:  Pharmacol Res       Date:  2021-01-29       Impact factor: 7.658

5.  Nestin expression is upregulated in the fibrotic rat heart and is localized in collagen-expressing mesenchymal cells and interstitial CD31(+)- cells.

Authors:  Vanessa Hertig; Kim Tardif; Marc Andre Meus; Natacha Duquette; Louis Villeneuve; Fanny Toussaint; Jonathan Ledoux; Angelino Calderone
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240

Review 6.  Can the onset of heart failure be delayed by treating diabetic cardiomyopathy?

Authors:  Anna Marcinkiewicz; Stanisław Ostrowski; Józef Drzewoski
Journal:  Diabetol Metab Syndr       Date:  2017-04-04       Impact factor: 3.320

Review 7.  Experimental models of cardiac physiology and pathology.

Authors:  Jae Gyun Oh; Changwon Kho; Roger J Hajjar; Kiyotake Ishikawa
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

8.  Resistin deletion protects against heart failure injury by targeting DNA damage response.

Authors:  Baoyin Zhao; Rihab Bouchareb; Djamel Lebeche
Journal:  Cardiovasc Res       Date:  2022-06-29       Impact factor: 13.081

9.  Phosphorylation of GATA4 at serine 105 is required for left ventricular remodelling process in angiotensin II-induced hypertension in rats.

Authors:  Alicia Jurado Acosta; Jaana Rysä; Zoltan Szabo; Anne-Mari Moilanen; Raisa Serpi; Heikki Ruskoaho
Journal:  Basic Clin Pharmacol Toxicol       Date:  2020-03-09       Impact factor: 4.080

10.  A role for calcium in resistin transcriptional activation in diabetic hearts.

Authors:  Rajvir Singh; Pedro Moreno; Roger J Hajjar; Djamel Lebeche
Journal:  Sci Rep       Date:  2018-10-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.